Paricalcitol [19-Nor-1,25-(OH)2D2] in the treatment of experimental renal bone disease

被引:17
作者
Jokihaara, J
Pörsti, I
Pajamäki, I
Vuohelainen, T
Jolma, P
Kööbi, P
Kalliovalkama, J
Niemelä, O
Kannus, P
Sievänen, H
Järvinen, TLN
机构
[1] Univ Tampere, Dept Surg, Sch Med, Tampere 33014, Finland
[2] Univ Tampere, Inst Med Technol, Tampere 33014, Finland
[3] Tampere Univ Hosp, Dept Surg, Tampere, Finland
[4] Univ Tampere, Dept Pharmacol Sci, FIN-33101 Tampere, Finland
[5] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland
[6] Univ Tampere, Dept Internal Med, FIN-33101 Tampere, Finland
[7] Tampere Univ Hosp, Dept Neurol & Rehabil, Tampere, Finland
[8] Etela Pohjanmaa Cent Hosp Lab, Dept Clin Chem, Seinajoki, Finland
[9] UKK Inst, Bone Res Grp, Tampere, Finland
关键词
bone; biomechanics; rodent; vitamin D;
D O I
10.1359/JBMR.060114
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Renal bone disease is a common consequence of chronic renal insufficiency and the associated secondary hyperparathyroidism (SH). Paricalcitol [19-nor-1,25(OH)(2)D-2] has been shown to ameliorate SH and prevent renal failure-induced histomorphometric changes in bone with minimal calcemic and phosphatemic activity. However, information about its efficacy on restoration of bone structural strength is lacking. In this study, we explored the effects of paricalcitol treatment on bone structure and strength in a model of advanced renal disease. Materials and Methods: Forty-five 8-week-old rats were randomly assigned to either surgical 5/6 nephrectomy (NTX) or Sham-operation. After a 15-week postoperative disease progression period, the NTX rats were further allocated to uremic control (NTX) and treatment (NTX + paricalcitol) groups, the latter of which received paricalcitol for the subsequent 12 weeks. After 27 weeks, the animals were killed, plasma samples were collected, and both femora were excised for comprehensive analysis of the femoral neck and midshaft (pQCT and biomechanical testing). Results: High mortality that exceeded 30% was observed in both NTX groups. NTX induced over a 13-fold increase in plasma PTH, whereas this increase was only 5-fold after paricalcitol treatment. At the femoral neck, NTX was associated with an 81% decrease (p < 0.05) in vBMD and a 16% decrease in breaking load (p < 0.05) compared with the Sham group, whereas paricalcitol treatment completely prevented these changes. At the femoral midshaft, the NTX resulted in a 6.6% decrease in cortical BMD (p < 0.01 versus Sham), and this change was also prevented by paricalcitol. Conclusions: Paricalcitol administration prevented renal insufficiency-associated decreases in BMD in the femoral neck and the femoral midshaft and restored bone strength in the femoral neck. Therefore, paricalcitol can efficiently ameliorate renal insufficiency-induced loss of bone mineral and mechanical competence of bone.
引用
收藏
页码:745 / 751
页数:7
相关论文
共 31 条
  • [1] Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport
    Brown, AJ
    Finch, J
    Slatopolsky, E
    [J]. JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2002, 139 (05): : 279 - 284
  • [2] Muscle strength, bone mass, and age-related bone loss
    Burr, DB
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (10) : 1547 - 1551
  • [3] On the evolving nature of understanding dialysis-related disorders
    Eknoyan, G
    Lindberg, JS
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) : S1 - S3
  • [4] Finch JL, 1999, J AM SOC NEPHROL, V10, P980
  • [5] Finch JL, 2001, J AM SOC NEPHROL, V12, P1468, DOI 10.1681/ASN.V1271468
  • [6] On our age-related bone loss: Insights from a new paradigm
    Frost, HM
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (10) : 1539 - 1546
  • [7] DEVELOPMENT OF ADYNAMIC BONE IN PATIENTS WITH SECONDARY HYPERPARATHYROIDISM AFTER INTERMITTENT CALCITRIOL THERAPY
    GOODMAN, WG
    RAMIREZ, JA
    BELIN, TR
    CHON, Y
    GALES, B
    SEGRE, GV
    SALUSKY, IB
    [J]. KIDNEY INTERNATIONAL, 1994, 46 (04) : 1160 - 1166
  • [8] VITAMIN-D-3 ANALOGS AND SALMON-CALCITONIN PARTIALLY REVERSE THE DEVELOPMENT OF RENAL OSTEODYSTROPHY IN RATS
    JABLONSKI, G
    MORTENSEN, BM
    KLEM, KH
    MOSEKILDE, L
    DANIELSEN, CC
    GORDELADZE, JO
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1995, 57 (05) : 385 - 391
  • [9] Estrogen deposits extra mineral into bones of female rats in puberty, but simultaneously seems to suppress the responsiveness of female skeleton to mechanical loading
    Järvinen, TLN
    Kannus, P
    Pajamäki, I
    Vuohelainen, T
    Tuukkanen, J
    Järvinen, A
    Sievänen, H
    [J]. BONE, 2003, 32 (06) : 642 - 651
  • [10] Revival of bone strength:: The bottom line
    Järvinen, TLN
    Sievänen, H
    Jokihaara, J
    Einhorn, TA
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (05) : 717 - 720